-transparent.png){kind=logo}
Ascending and descending segments of the rat colon were studied to analyze their contractile responses to neuropeptide Y and related peptides. These responses are (a) completely eliminated by tetrodotoxin (1 microM), (b) reduced to a variable extent (20 to 60%) by atropine (1 microM) and (c) not modified by indomethacin, diphenhydramine or methysergide. The order of potency of agonists for peptides related to neuropeptide Y was as follows: human pancreatic polypeptide = rat pancreatic polypeptide > peptide YY = peptide YY-(3-36) = [Leu31,Pro34]neuropeptide Y > neuropeptide Y-(2-36) > C2-neuropeptide Y = neuropeptide Y > neuropeptide Y-(13-36), with minor differences observed between the two parts of the colon. This selectivity pattern does not correspond to the profile of any known cloned neuropeptide Y receptors. BIBP3226, a selective antagonist for the neuropeptide Y Y1 receptor sub-type, was found to be inactive, while a neuropeptide Y Y2 receptor antagonist, T4-[NPY-(33-36)]4, reduced the effects of neuropeptide Y, peptide YY, peptide YY-(3-36) and C2-neuropeptide Y without affecting those of human pancreatic polypeptide, rat pancreatic polypeptide and [Leu31,Pro34]neuropeptide Y. JCF 104 (compound 28), a putative neuropeptide Y Y5 receptor antagonist, showed no effect or a weak inhibition of human pancreatic polypeptide or [Leu31,Pro34]neuropeptide Y-induced contraction. Taken together, these data suggest that: (1) at least two neuropeptide Y receptor types are present in the rat colon autonomic nerve terminals and modulate the release of acetylcholine and possibly other transmitters; (2) a proportion of the receptors mediating the contractile response of the rat colon (especially descending part) to neuropeptide Y and related peptides appears to be of the Y2 type and (3) the significant portion of the response is mediated by a receptor which is insensitive to neuropeptide Y Y1, Y2 and to neuropeptide Y Y5 receptor antagonists. This receptor behaves as a neuropeptide Y Y4 receptor sub-type and appears to be located on enteric nerves.
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
March 2002,
British journal of pharmacology,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
August 2003,
European journal of pharmacology,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
October 1997,
The American journal of physiology,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
January 1998,
Neurotoxicology and teratology,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
January 1999,
Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
January 2005,
Neuroscience,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
May 1993,
Journal of cardiovascular pharmacology,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
March 1989,
FEBS letters,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
May 2002,
Peptides,
L H Pheng, and
A Perron, and
R Quirion, and
A Cadieux, and
J L Fauchère, and
Y Dumont, and
D Regoli
March 2007,
Expert review of endocrinology & metabolism,
